Migraine without Aura

Recurrent unilateral pulsatile headaches, not preceded or accompanied by an aura, in attacks lasting 4-72 hours. It is characterized by PAIN of moderate to severe intensity; aggravated by physical activity; and associated with NAUSEA and / or PHOTOPHOBIA and PHONOPHOBIA. (International Classification of Headache Disorders, 2nd ed. Cephalalgia 2004: suppl 1)

Drugs by status

Organizations

Organization Involved with Phase 4 Indications (6)

California Medical Clinic for Headache
University of Alberta
Kecioren Education and Training Hospital
Janssen Pharmaceutica NV
Canadian Institutes of Health Research (CIHR)
Johnson and Johnson

Organization Involved with Phase 3 Indications (11)

Pfizer
Ipsen
Lotus Pharmaceutical
Shahid Beheshti University of Medical Sciences
Diamond Headache Clinic
Norwegian University of Science and Technology
Taipei Veteran General hospital
Norwegian National Headache Centre
Chiangmai University
Rajavithi Hospital, Bangkok
Satsuma Pharmaceuticals, Inc.

Organization Involved with Phase 2 Indications (14)

Takeda
Ariston Pharmaceuticals, Inc.
Minster Research Ltd
NeurAxon Inc.
Nektar Therapeutics
Solvay
Canisius-Wilhelmina Hospital
University of London
University of Washington
University of Connecticut
University of Montreal
Dr. Reddy's Laboratories
Yeshiva University
Corona Doctors Medical Clinics, Inc.

Organization Involved with Phase 1 Indications (1)

Quotient

Organization Involved with Other Experimental Indications (9)

Novartis
Danish Headache Center
University of Rochester
Netherlands Organisation for Scientific Research
University of Copenhagen
Leiden University
European Commission
Lundbeck
Cool Sorption Foundation of 1988

ICD-10 crosswalk

G43.0 — Migraine without aura